In domestic and foreign studies, experts and scholars have also proposed some intervention measures to promote functional exercise compliance in patients with Parkinson’s disease. For example, incorporating functional exercise into routine behaviors of patients’ daily lives, providing personalized exercise guidance and advice, and support from relatives, doctors, and the community. These interventions can not only remind and motivate patients to exercise but also improve patients’ exercise motivation and effectiveness. In addition, some studies have found that functional exercise compliance in patients with Parkinson’s disease can be improved by using new types of exercise equipment, such as the handheld Tai Chi water resistance fitness ball. This kind of exercise equipment has the advantages of simplicity, wide applicability and obvious effect, and has great potential for functional exercise of patients with Parkinson’s disease.
In general, there are some problems in the status quo of functional exercise compliance of Parkinson’s patients at home and abroad, which need to be paid attention to. Through understanding and analyzing these problems, we can provide some reference and basis for designing and carrying out intervention measures. It is hoped that this study can further investigate the status quo of functional exercise compliance in patients with Parkinson’s disease, and provide effective intervention measures to improve patients’ exercise compliance and quality of life. At the same time, we also hope to use the advantages of the handheld Tai Chi water resistance fitness ball to promote the functional exercise effect and compliance of Parkinson’s patients.
Author(s) Details:
He Huang
Independent Researcher, 2308 Ruth Ct, Rowland Heights, CA 91748, Los Angeles, USA.
Recent Global Research Developments in Clinical Features of Parkinson’s Disease
Diagnostic Test for Parkinson’s Disease:
- A small trial published in the journal Nature Medicine describes a diagnostic test for Parkinson’s disease. Researchers developed this test using samples of cerebrospinal fluid to measure a person’s levels of abnormal alpha synuclein, a protein implicated in the disease. If granted full approval by the U.S. Food and Drug Administration (FDA), it will become the first test for diagnosing Parkinson’s [1].
- This breakthrough is crucial because accurate diagnosis is essential for effective management and treatment.
Potential Immune-Based Treatment:
- The same study also introduces a potential immune-based treatment developed by the Florida-based biotech company Vaxxinity. They created a vaccine (referred to as an “active immune medicine”) to train the immune system to target only abnormal forms of alpha synuclein, leaving regular forms untouched.
- The idea is that patients’ immune systems recognize their own misfolded proteins, leading to self-treatment. While still in early stages, this approach holds promise for Parkinson’s patients [1].
Other Advances in Parkinson’s Research:
- Over the past two decades, there have been significant advances in Parkinson’s disease research. These include regulatory approvals for deep brain stimulation, levodopa plus carbidopa intrajejunal, and MRgFUS (magnetic resonance-guided focused ultrasound) treatments [2].
- Additionally, ongoing studies explore risk factors, pathophysiology, and novel therapeutic strategies [3].
References
- A Potential Parkinson’s Treatment Has Promising Results
https://time.com/6883054/parkinsons-test-vaccine-study-vaxxinity/ - Obeso, J. A., Monje, M. H., & Matarazzo, M. (2022). Major advances in Parkinson’s disease over the past two decades and future research directions. The Lancet Neurology, 21(12), 1076-1079.
- Li, S., Jia, C., Li, T. et al. Hot Topics in Recent Parkinson’s Disease Research: Where We are and Where We Should Go. Neurosci. Bull. 37, 1735–1744 (2021). https://doi.org/10.1007/s12264-021-00749-x
- Deliz, J.R., Tanner, C.M. & Gonzalez-Latapi, P. Epidemiology of Parkinson’s Disease: An Update. Curr Neurol Neurosci Rep 24, 163–179 (2024). https://doi.org/10.1007/s11910-024-01339-w
